Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

China flag China · Delayed Price · Currency is CNY
29.88
+0.81 (2.79%)
Apr 29, 2026, 4:00 PM EDT
6.68%
Market Cap 2.68B
Revenue (ttm) 412.51M
Net Income (ttm) 37.59M
Shares Out 89.68M
EPS (ttm) 0.42
PE Ratio 71.57
Forward PE n/a
Dividend 0.09 (0.31%)
Ex-Dividend Date Jun 12, 2025
Volume 1,539,800
Average Volume 1,190,712
Open 28.89
Previous Close 29.07
Day's Range 28.71 - 30.37
52-Week Range 26.88 - 39.28
Beta 0.56
RSI 41.57
Earnings Date Apr 23, 2026

About SHE:301258

Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; l-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonst... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 524
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301258
Full Company Profile

Financial Performance

In 2025, SHE:301258's revenue was 432.73 million, an increase of 0.76% compared to the previous year's 429.47 million. Earnings were 64.29 million, an increase of 291.89%.

Financial Statements

News

There is no news available yet.